Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
Top Page
BioLife Solutions
(NASDAQ:BLFS)
54Neutral
Positive Factors
Financial Performance
BioLife Solutions reported strong financial performance in 4Q24, with total revenue exceeding projections and a net loss lower than expected.
Mergers and Acquisitions
BioLife completed the acquisition of PanTHERA CryoSolutions, a privately held developer of novel cryopreservation solutions, which strengthens BioLife’s market leading position in biopreservation.
Product Demand
BioLife’s biopreservation media was embedded in 17 unique approved cell and gene therapies, and 10 additional approvals, geographic expansions or new indications could occur in the coming 12 months.
Negative Factors
Industry Uncertainty
Potential long-term impact from changes in leadership at the FDA and NIH budget uncertainty is still too early to quantify.
Missed Projections
Biolife reported 1Q25 results with revenue of $23.9M, up 33% y/y, and ended the period with $108M in cash which should be sufficient to fund existing operations.
Revenue Decline
Total revenue was $23.9M, representing a 24.5% YoY decline and missing our projection of $26.0M.
BioLife Solutions (BLFS) vs. S&P 500 (SPY)
Market Cap
$1.12B
Dividend YieldN/A
Average Volume (3M)663.66K
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue Growth-23.12%
EPS Growth97.46%
CountryUS
Employees159
SectorHealthcare
Sector Strength41
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.01
Shares Outstanding47,561,172
10 Day Avg. Volume768,921
30 Day Avg. Volume663,658
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)3.43
Price to Sales (P/S)0.00
P/FCF Ratio248.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.43Price Target Upside33.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
BioLife Solutions Business Overview & Revenue Model
Company DescriptionBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
How the Company Makes MoneyBioLife Solutions generates revenue through the sale of its proprietary biopreservation media and automated thawing systems. These products are essential for maintaining the viability and potency of sensitive biological materials during transport and storage. The company's revenue streams include direct sales to biotechnology and pharmaceutical companies, as well as academic and research institutions involved in cell and gene therapy development. Additionally, BioLife Solutions benefits from strategic partnerships and collaborations that enhance its market reach and technological capabilities, contributing to its financial performance.
BioLife Solutions Financial Statement Overview
Summary
BioLife Solutions faces challenges in profitability and revenue growth, with negative margins and decreased revenues impacting the income statement. The balance sheet shows a strong equity base but has been weakened by recent negative equity. Cash flow performance is mixed, highlighting the need for better cash management strategies. The company must focus on improving operational efficiency and profitability to enhance financial health.Income Statement
BioLife Solutions has experienced a significant decline in revenue and profit margins. The revenue growth rate shows a downward trend, and both EBIT and EBITDA margins are negative, indicating operational challenges. The company also struggles with negative net income, reflecting a need for operational improvements.40
Negative
Balance Sheet
The company has a strong equity base with a low debt-to-equity ratio, indicating minimal leverage risks. However, the negative stockholders' equity in recent years raises concerns about the company's financial stability. The equity ratio suggests a solid asset base, but the historical negative equity needs addressing.65
Positive
Cash Flow
Cash flow generation has been inconsistent, with occasional positive free cash flow but primarily negative trends. The operating cash flow to net income ratio indicates some cash generation ability despite net losses. Overall, cash flow management needs improvement to ensure sustainability.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 82.25M | 143.27M | 161.76M | 119.16M | 48.09M | Gross Profit |
| 57.75M | 46.75M | 53.82M | 37.75M | 27.44M | EBIT |
| -7.13M | -70.83M | -39.91M | -30.37M | -3.33M | EBITDA |
| 1.53M | -45.24M | -23.19M | -17.78M | 1.07M | Net Income Common Stockholders |
| -20.18M | -66.43M | -139.81M | -8.38M | 2.67M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 104.58M | 51.70M | 64.06M | 69.87M | 90.46M | Total Assets |
| 399.49M | 412.71M | 450.23M | 552.60M | 234.83M | Total Debt |
| 25.18M | 42.69M | 43.71M | 26.88M | 11.15M | Net Debt |
| -70.21M | 7.28M | 24.27M | -42.99M | -79.30M | Total Liabilities |
| 50.58M | 75.05M | 86.04M | 71.85M | 29.58M | Stockholders Equity |
| 348.91M | 337.66M | -246.91M | 480.75M | 205.25M |
| Cash Flow | Free Cash Flow | |||
| 5.20M | -18.88M | -18.87M | -13.22M | 1.88M | Operating Cash Flow |
| 8.43M | -12.50M | -8.49M | -4.84M | 6.51M | Investing Cash Flow |
| 58.30M | 17.84M | -58.12M | -12.64M | -23.73M | Financing Cash Flow |
| -6.78M | 10.59M | 16.32M | -2.78M | 101.22M |
BioLife Solutions Technical Analysis
Neutral
23.59
Price Trends
23.76
Negative
25.21
Negative
24.94
Negative
Market Momentum
-0.23
Positive
51.39
Neutral
33.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Neutral. The current price of 23.59 is above the 20-day moving average (MA) of 23.40, below the 50-day MA of 23.76, and below the 200-day MA of 24.94, indicating a neutral trend. The MACD of -0.23 indicates Positive momentum. The RSI at 51.39 is Neutral, neither overbought nor oversold. The STOCH value of 33.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BLFS.
BioLife Solutions Risk Analysis
BioLife Solutions disclosed 34 risk factors in its most recent earnings report. BioLife Solutions reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLife Solutions Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.12B | ― | -3.29% | ― | -23.12% | 97.46% | |
54 Neutral | $1.26B | ― | -2.00% | ― | -2.76% | 48.51% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
52 Neutral | $951.89M | 55.81 | -19.14% | ― | -14.44% | -557.38% | |
44 Neutral | $1.16B | ― | -77.86% | ― | ― | -1.00% | |
34 Underperform | $1.26B | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
BLFS
BioLife Solutions
23.59
1.76
8.06%
AZTA
Azenta
27.47
-24.01
-46.64%
STAA
Staar Surgical
19.22
-23.58
-55.09%
PLSE
Pulse Biosciences
17.19
8.61
100.35%
NNNN
Anbio Biotechnology Class A
7.54
1.87
32.98%
KMTS
Kestra Medical Technologies Ltd.
24.62
3.63
17.29%
BioLife Solutions Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 5.50%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong start to 2025 with significant revenue growth and improved profitability. A strategic acquisition and a robust financial position further highlight BioLife's positive trajectory. Potential challenges from industry headwinds were acknowledged, but their impact is not expected to be material in the near term.Q1-2025 Updates
Positive Updates
Strong Revenue Growth
Total revenue increased by 30% year-over-year, with cell processing revenue up 33%. This marks the sixth consecutive quarter of revenue growth.
Enhanced EBITDA Margin
Adjusted EBITDA margin expanded to 24%, up from 14% in the prior year, demonstrating strong operational efficiency.
Acquisition of PanTHERA CryoSolutions
The acquisition expands BioLife's biopreservation portfolio and enhances scientific capabilities, reinforcing its leadership in bioproduction consumables.
Strong Financial Position
BioLife ended the quarter with over $100 million in cash, providing a solid foundation for future growth.
Reaffirmed Financial Guidance
BioLife reaffirmed its full-year revenue guidance of $95.5 million to $99 million, with expected growth led by the cell processing platform.
Negative Updates
Operating Expenses Increase
GAAP operating expenses for Q1 2025 were $25.2 million, up from $21.7 million in Q1 2024, due to increased cost of sales and acquisition-related fees.
Potential Industry Headwinds
Near-term uncertainty from tariffs, NIH funding cuts, and FDA leadership changes could create headwinds across the ecosystem, though no material impact is expected currently.
Company Guidance
In the first quarter of 2025, BioLife Solutions delivered a strong financial performance, with cell processing revenue increasing by 33% year-over-year to $21.6 million, contributing to a total revenue of $23.9 million, up 30% from the previous year. The company also reported an adjusted EBITDA margin of 24%. BioLife's core biopreservation media (BPM) product line remains a key driver, with 60% of BPM revenue coming from direct sales and 40% from distribution. Notably, 40% of total BPM revenue is derived from customers with approved commercial therapies. At the end of Q1, BioLife's BPM products were used in 17 approved therapies, with an estimated 70% usage in U.S. commercially sponsored CGT trials. The company reaffirmed its full-year revenue guidance of $95.5 million to $99 million, forecasting 16% to 20% growth. Adjusted gross margin is expected to remain in the mid-60% range.BioLife Solutions Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
Positive
Dec 20, 2024
BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors effective January 2, 2025. Mr. Hunt, recognized for his leadership in bioprocessing innovation, is expected to enhance BioLife’s strategic focus on the CGT market with his extensive industry experience, contributing to the company’s growth and innovation efforts. This appointment reflects BioLife’s commitment to strengthening its position in the bioprocessing sector and supporting its mission of delivering top-tier bioproduction workflows.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.